1. Scrip
  2. >>Business
  3. >>Strategy

Genfit Not Fully Exiting NASH, Despite Terminating RESOLVE-IT

 
• By Joseph Haas

A fuller look at interim Phase III data shows no path forward to accelerated approval in NASH, company says. Genfit turns focus to developing elafibranor for PBC, as well as a NASH diagnostic.

businessman has to decide which direction is better
Genfit reached a tough decision to end RESOLVE-IT and focus on other business

Genfit SA said on 22 July that it is terminating the Phase III RESOLVE-IT study of elafibranor in non-alcoholic steatohepatitis following an in-depth review of interim data, first unveiled in May, which showed the PPAR alpha/delta agonist missed its primary endpoint of resolving NASH without worsening of fibrosis. The French firm also said it now will focus its business on two efforts: Phase III development of elafibranor for primary biliary cholangitis and advancement of its NIS4 biomarker test as an in vitro diagnostic for NASH treatment.

The interim top-line results from the pivotal NASH study were a major blow for Genfit, when they showed a 19.2%...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

MBX Awaits Value-Creating Milestones, With Phase II Hypoparathyroidism Data Due Any Day

 
• By Mandy Jackson

MBX Biosciences uses its Precision Endocrine Peptide (PEP) platform to create hormone therapeutics with improved efficacy, durability and tolerability in rare diseases and obesity.

The Expanding MASH Market: How Rezdiffra, Wegovy Might Coexist

 
• By Joseph Haas

FDA approval of Novo Nordisk's Wegovy for MASH was almost as anticipated as approval of the first drug, Madrigal's Rezdiffra. Now, the MASH treatment paradigm should evolve.

Deal Watch: XOMA Buys Troubled Alkermes-Spinout Mural Oncology

 
• By Joseph Haas, Xu Hu, and Lisa Takagi

Plus deals involving Fosun/Accro, Fosun/Sitala, RemeGen/Santen, Firebird/Solasia and more, including tech transfer.

Norway’s Nykode Upbeat About Cancer Vaccines After Tough Year

 
• By Kevin Grogan

The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.

More from Business

Novo Adds Another Prong To Its RNA Ambitions With Replicate Deal

 
• By Jessica Merrill

Replicate is a clinical-stage company developing a next-generation self-replicating RNA technology. CEO Nathanial Wang talked to Scrip about the deal.

Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals

 
• By Andrew McConaghie

Superluminal’s CEO Cony D’Cruz believes its focus on GPCRs has already yielded a best-in-class obesity candidate for its own pipeline, as well as its $1bn- plus deal with Eli Lilly.

Norway’s Nykode Upbeat About Cancer Vaccines After Tough Year

 
• By Kevin Grogan

The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.